+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hyperhidrosis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 4987225
  • Report
  • June 2022
  • Region: Global
  • 116 Pages
  • Mordor Intelligence
The Hyperhidrosis Treatment Market was valued at USD 1,560.18 million in 2021, and it is expected to reach USD 1,967.09 million by 2027, at a CAGR of nearly 4.07% during the forecast period, 2022-2027.

The COVID-19 outbreak is an unprecedented health concern and has significantly impacted the hyperhidrosis treatment market worldwide. Presently, countries globally are facing difficulties in accessing certain therapeutics due to lockdown restrictions and the introduction of new COVID-19 variants. As per a January 2021 published article titled, Paroxysmal hypothermia and hyperhidrosis with exacerbation after COVID‑19 infection, during the acute phase of the COVID-19 infection, periods of hypothermia alternated with fever for four days. The same source also reports that after the recovery phase, however, episodic hyperhidrosis and hypothermia persisted without fever despite the use of clonidine. Thus, the demand for hyperhidrosis treatment has increased. However, with the pandemic still in its growth phase, the market players are witnessing a significant impact of the COVID-19. According to the International Hyperhidrosis Society, sweat could actually help prevent the transmission of COVID-19. The organization supports that claim with quotes from experts like dermatologist Adam Friedman of the George Washington University, who noted that "Sweat has some inherent antimicrobial activity." However, COVID-19's immediate and direct potential impact has already led to the loss of millions of lives and a considerable increase in healthcare costs.

The key factors bolstering the hyperhidrosis treatment market growth are the rise in prevalence of secondary hyperhidrosis conditions and the increase in investments by the market players for research and development.

Some other factors that could potentially impact the market growth are the promising pipeline for hyperhidrosis treatment, the growing prevalence of depression and anxiety, growing awareness pertaining to hyperhidrosis, and the presence of favorable reimbursement policies. For instance, the International Hyperhidrosis Society provides useful tools, information, and downloadable forms related to the insurance and reimbursement process. In view of the aforementioned factors, some of the market players across the globe are engaged in the manufacture and provision of hyperhidrosis treatment products.

Moreover, these market players engage in inorganic and organic strategies, including expansions, product launches, acquisitions, collaborations, mergers, and partnerships, to establish a strong presence and expand their geographical reach. For instance, in April 2021, Fortress Biotech, partner company Journey Medicals, entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the USA from Dermira, a wholly-owned subsidiary of Eli Lilly. Thus, owing to these factors, the studied market is expected to witness growth. However, the short-term results of cosmetic and therapeutic procedures are a major factor restraining the growth of the hyperhidrosis treatment market.

Key Market Trends

Botulin Toxin A is Expected to Hold the Largest Market Share in the Hyperhidrosis Treatment Market

Botulinum toxin type A is a safe and effective treatment for focal hyperhidrosis that lasts longer than topical treatments and does not require invasive surgical procedures. Botulinum toxin injections are most commonly used to treat axillary hyperhidrosis, but they can also be used to treat palmar and plantar disease. Botulinum toxin's effects last six to nine months on average, and treatment is linked to a high satisfaction rate among patients.

BOTOX (onabotulinumtoxinA) was approved by the US Food and Drug Administration (FDA) in 2004 for the treatment of severe primary axillary hyperhidrosis (excessive sweating of the underarms) in patients who were unable to find relief with antiperspirants. AbbVie Inc. owns BOTOX, which is the most researched botulinum toxin in the world. BOTOX has been approved for the treatment of excessive sweating in the underarms in at least 20 countries. It can also be used off-label to treat sweating in the face, feet, and hands.

Excessive sweating of the armpits, hands, feet, head, and face (craniofacial) and other relatively small body areas (like under the breasts) can be treated with onabotulinumtoxinA, as per the article published in International Hyperhidrosis Society of 2020. Botox has been shown to reduce sweating by 82-87% when used to treat excessive sweating under the arms. The effects begin to show up 2 to 4 days after treatment, with the full effects usually appearing within two weeks. Dryness lasts 4 to 12 months on average, but some studies have found that it can last up to 14 months.

Numerous studies have demonstrated its efficacy in reducing anxiety. For example, according to a study published in the journal Scientific Reports in 2021, people who received Botox injections at four different sites reported anxiety significantly less frequently than those who received different treatments for the same conditions. The risk of anxiety was found to be reduced by 22-72% in Botox patients.

Hence, the effectiveness of Botox in treating hyperhidrosis and its long-lasting effect is driving the market growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall hyperhidrosis treatment market throughout the forecast period. The United States holds a significant share in the hyperhidrosis treatment market in North America. The increasing burden of primary hyperhidrosis, cancer, and cardiovascular disorders increases secondary hyperhidrosis, technological advancements, and the presence of key market players in the country.

The high prevalence of primary and secondary hyperhidrosis will increase the adoption of treatment in the country. For instance, a research paper published in October 2021 in the United States National Library of Medicine titled hyperhidrosis stated that it affects approximately 3% of the United States population and is most common in patients between 20 to 60 years of age. The high prevalence has increased the adoption of various treatments such as over-the-counter aluminum chloride hexahydrate 20% in the country. Such prevalence will increase the demand for product consumption which will increase the growth of the market.

According to the article named Prevalence of Cardiovascular Disease in Adults, published in February 2020, roughly 47% of adults had at least one of the three key risk factors for CVD (hypertension, 78 million; high LDL cholesterol, 1 million; smoking, 34.2 million). Men were more likely than women to have at least one of these risk factors. Hypertension was the most prevalent risk factor (24.8%) among all adults, and the difference between men and women (7.4% men vs. 4.1% women) was smallest (1.1%) for hypertension and greatest (35.3%) for coronary heart disease. With increasing age, the three risk factors had similar but disproportionate rates of increase. Increasing CVD will increase secondary hyperhidrosis, which will increase the demand for the hyperhidrosis treatment market in the future.

Furthermore, increasing research and development activities for hyperhidrosis treatment products in the United States will lead to higher adoption of these products, thereby expected to drive the growth of this market in the United States. For instance, in October 2021, Brickell Biotech Inc. announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies, which evaluated sofpironium bromide gel, 15% as a once-daily topical formulation in patients with primary axillary hyperhidrosis.

Similarly, in January 2019, the Journal of the American Academy of Dermatology named “Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials” stated that Glycopyrronium tosylate (GT) applied topically on a daily basis over four weeks reduced the severity of sweating as measured by ASDD-Item 2, reduced sweat production as measured gravimetrically, and was generally well-tolerated in patients with primary axillary hyperhidrosis. Such initiatives increase the number of innovative products in the market, in turn increasing the growth of the market in the near future.

Due to the above-mentioned factors, the market is expected to drive swiftly in the forecast period in the United States.

Competitive Landscape

The hyperhidrosis treatment market is moderately consolidated and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions with the other companies to consolidate their market positions globally (Sientra acquired Miramar). Some of the market players are Abbvie, Brickell Biotech, Eli Lilly And Company (Dermira), Advin Healthcare, and Dermavant Scienecs Inc. (Roivant Sci).

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Secondary Hyperhidrosis Condition
4.2.2 Increase in Investments by Market Players for Research and Development
4.3 Market Restraints
4.3.1 Short-term Results of Cosmetic and Therapeutic Procedures
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Treatment Type
5.1.1 Topical Treatments
5.1.2 Surgical Treatments
5.1.3 Botulin toxin A
5.1.4 Iontophoresis
5.1.5 Laser Treatments
5.1.6 Other Treatment Types
5.2 By Disease Type
5.2.1 Primary Focal Hyperhidrosis
5.2.2 Secondary Generalized Hyperhidrosis
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 AbbVie Inc. (Allergan PLC)
6.1.2 Brickell Biotech Inc.
6.1.3 Eli Lilly And Company (Dermira)
6.1.4 1315 Capital (miraDry Inc.)
6.1.5 SweatBlock
6.1.6 Merz Pharma (Merz Aesthetics)
6.1.7 Dermavant Sciences Inc. (Roivant Sciences)
6.1.8 Advin Health Care
6.1.9 Dermadry Laboratories Inc.
6.1.10 Dermata Therapeutics Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc. (Allergan PLC)
  • Brickell Biotech Inc.
  • Eli Lilly And Company (Dermira)
  • 1315 Capital (miraDry Inc.)
  • SweatBlock
  • Merz Pharma (Merz Aesthetics)
  • Dermavant Sciences Inc. (Roivant Sciences)
  • Advin Health Care
  • Dermadry Laboratories Inc.
  • Dermata Therapeutics Inc.